The respiratory syncytial virus (RSV) market looks set for disruption with vaccines from Pfizer Inc. and GSK plc moving towards approval and AstraZeneca PLC/Sanofi's long-acting monoclonal antibody Beyfortus recently getting the thumbs-up in the EU, but Synagis, the old standard of care from Swedish Orphan Biovitrum AB (Sobi), is still holding its own commercially.
Sobi Maintains Grip On RSV Market – For Now
Though Competition Is Coming
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.
